top of page

Psychological Encyclopedia

Bipolar Spectrum: Meaning, Clinical Uses, and Diagnostic Limits

7 days ago
18 min read

Author: Ukrainian Psychological Hub · Published: October 9, 2026 · Editorial Policy

The term bipolar spectrum describes a proposed range of mood patterns and conditions that share some characteristics with established bipolar disorders. In research and clinical discussion, it can encompass formally diagnosed bipolar I disorder, bipolar II disorder, and cyclothymic disorder, together with various subthreshold or atypical presentations. Its precise reach changes with the author, study, and operational criteria. That variability is central to understanding the term: bipolar spectrum is a useful descriptive and research framework, but it is not itself an additional diagnosis recognized as a single disorder in DSM-5-TR or ICD-11. NIMH and the CANMAT/ISBD guideline summary describe established diagnostic categories and clinical management.

The practical question is how clinicians recognize patterns of possible bipolarity that deserve careful investigation while avoiding an interpretation in which ordinary mood variation, insomnia, enthusiasm, irritability, or brief fluctuations automatically become evidence of disease. This article examines the clinical meaning, competing definitions, research findings, assessment methods, treatment implications, and diagnostic limits of the bipolar spectrum. Its focus is the spectrum construct itself; the diagnostic criteria and comprehensive treatments of individual bipolar disorders are explained in their separate articles.

What does bipolar spectrum mean?

In its narrowest usage, bipolar spectrum is simply an umbrella expression for recognized bipolar and related disorders. A broader usage includes people who have some elevated or activated mood symptoms, unusually recurrent mood episodes, or episodic patterns suggestive of bipolarity without meeting the full criteria for a particular diagnosis. Some research definitions include short-duration hypomania, hypomania with too few accompanying symptoms, or depressive disorders accompanied by particular lifetime hypomanic features. Other proposals extend further to temperamental traits, family history, or treatment-associated activation. These are different constructs; their findings should not be merged as if they describe one clinically verified population. Cassano and colleagues outlined the spectrum hypothesis and its unresolved validation questions, and Nusslock and Frank examine the challenges of subthreshold presentations.

A spectrum is a model of variation in clinical features, severity, duration, and course. It does not mean that everyone belongs somewhere on a disease scale, nor does a higher score on a questionnaire establish placement on such a scale. The model can help a clinician formulate questions and decide which episodes to investigate; a clinical diagnosis still requires its own evidence. The distinction matters because diagnostic labels influence medication decisions, expectations of recurrence, access to services, and how a person interprets their history.

Bipolar spectrum versus a formal bipolar diagnosis

Recognized bipolar and related disorders

Bipolar I disorder requires a history of a manic episode meeting diagnostic criteria, even when a major depressive episode has never occurred. Bipolar II disorder involves at least one hypomanic episode and at least one major depressive episode, in the absence of a lifetime manic episode. Cyclothymic disorder involves an extended course of fluctuating hypomanic and depressive symptoms that do not individually meet full episode criteria, with duration and persistence requirements. Other specified bipolar and related disorder and unspecified bipolar and related disorder provide recognized categories when bipolar-type presentations cause clinical concern but do not meet the complete criteria of the preceding disorders, under the relevant classification rules. NIMH provides an accessible account of these types.

The phrase bipolar spectrum does not replace those categories. A person may be described informally as having possible spectrum features and subsequently receive a formal bipolar diagnosis, another psychiatric diagnosis, or no bipolar diagnosis after thorough assessment. The category other specified bipolar and related disorder, when applicable, is a formal diagnostic category; the generic phrase subthreshold bipolarity may instead be a research classification. They should not be treated as synonyms. The 2023 CANMAT/ISBD summary discusses care across defined bipolar presentations.

Mania, hypomania, and milder activation

Mania is an episode of abnormally and persistently elevated, expansive, or irritable mood and increased energy or activity, accompanied by characteristic additional symptoms and serious clinical significance. A typical full manic episode lasts at least one week, or a shorter period when hospitalization is necessary; psychotic features also make an episode manic rather than hypomanic. Hypomania involves a distinct change lasting at least four consecutive days, observable to others but without the marked impairment, hospitalization requirement, or psychosis associated with mania. A manic or hypomanic state involves a change from the person's usual functioning, not simply an energetic personality. NIMH; NICE CG185.

Subthreshold activation is a descriptive term for experiences that fall short of a full episode in duration, symptom count, severity, or other criteria. A two-day period of greatly reduced need for sleep, unusual confidence, accelerated speech, and conspicuous increased activity may warrant documentation and follow-up, particularly if it recurs. Yet two days is not automatically a DSM hypomanic episode. Reduced need for sleep is also different from being unable to sleep while exhausted: in true elevated-state histories, the individual may sleep little without the usual fatigue. A clinical interview evaluates that distinction along with substance exposure, context, and observable change.

Bipolar II disorder is not a milder form of bipolar I disorder

The absence of full mania in bipolar II does not imply trivial illness. Major depressive episodes may be prolonged or disabling, and impairment can be substantial even when hypomania itself seems productive or enjoyable. Severity must be assessed in the actual person's depressive course, functioning, comorbid conditions, and safety risk. Likewise, the presence of a few hypomanic features during depression does not automatically establish bipolar II. Full episode histories, clinical thresholds, and differential diagnosis remain essential. See the NIMH overview and NICE guidance.

Why clinicians and researchers use a bipolar spectrum concept

Recognizing mood symptoms below conventional thresholds

Diagnostic thresholds are necessary for reliable communication and treatment research, but people can experience recurrent and impairing symptoms whose duration or count falls just outside a named episode. A spectrum formulation helps document those presentations without pretending that a borderline symptom count is proof of an established disease. Researchers can then ask whether subthreshold experiences are associated with distress, impaired functioning, future episodes, or different treatment responses. The early clinical framework proposed by Cassano and colleagues specifically called for further research to test the validity of this broader construct.

Identifying depression histories that merit investigation for hypomania

A major depressive episode is often the reason a person first seeks treatment, whereas earlier periods of elevated energy, decreased sleep, or excessive activity may have seemed welcome or unremarkable. Asking about such periods is clinically useful even if the final formulation remains major depressive disorder. In a longitudinal clinical sample of 550 people originally diagnosed with major depression, Fiedorowicz and colleagues found that certain subthreshold hypomanic symptoms predicted subsequent syndromal mood elevation. The study demonstrates that some symptom histories carry prognostic information; its selected treatment-seeking sample and long follow-up period should not be turned into a prediction that most people with depression will develop bipolar disorder.

Improving the measurement of mood patterns

Spectrum studies sometimes measure lifetime fluctuations, symptom dimensions, and temperament across diagnoses. This approach can illuminate correlations and clinical heterogeneity that categorical diagnostic comparisons miss. Its scientific validity depends on transparent definitions, representative sampling, dependable retrospective reports, adequate follow-up, and the demonstration of clinically meaningful outcomes. A study that classifies short activation periods as spectrum illness measures a different population from one that counts only formally diagnosed disorders. Meaningful replication requires stating those criteria openly. Merikangas and colleagues illustrate how an epidemiologic definition of subthreshold bipolarity can be made operational.

How broad is the spectrum? Competing definitions

The diagnostic-family definition

This approach groups bipolar I, bipolar II, cyclothymic, other specified, and unspecified bipolar presentations without proposing a completely new disease category. It is the most straightforward usage when discussing existing clinical diagnoses, although each still retains its own criteria and treatment evidence. Diagnostic families are classifications, rather than claims that a single biological process explains every case. NIMH; CANMAT/ISBD.

The subthreshold-episode definition

This narrower expansion looks for clinically meaningful mood elevation that narrowly misses full hypomania or mania criteria: a shorter duration, an insufficient number of symptoms, or a differently specified pattern. Researchers may evaluate whether such episodes predict later diagnosable bipolar disorder, but the risk differs by sample and episode definition. Evidence from longitudinal depression cohorts supports attention to repeated elevated-state symptoms without making them deterministic. Fiedorowicz et al.; Nusslock and Frank.

The broad phenotype or temperament definition

Some historical and theoretical models also include affective temperament, recurrent depression, family history, highly variable energy levels, or responses to medication. These properties can be relevant to assessment, but they are not interchangeable with distinct hypomanic episodes. A family history raises prior probability in an appropriate context; it cannot establish a diagnosis. A temperament questionnaire measures traits and tendencies; it does not prove an illness. Broad models may identify more people at the cost of lower specificity. The history of these proposals is outlined in Cassano and colleagues, while Nusslock and Frank discuss operational challenges.

What does research show about prevalence?

Prevalence estimates for bipolar spectrum are definitions, measures, populations, and time periods expressed as numbers. They should always name the underlying categories. In the US National Comorbidity Survey Replication, involving 9,282 adults, Merikangas and colleagues estimated lifetime prevalence of bipolar I disorder at 1.0%, bipolar II disorder at 1.1%, and their study-defined subthreshold bipolar disorder at 2.4%, giving a combined spectrum estimate of 4.4%. These were results from a DSM-IV-era epidemiologic interview and a specified research definition, not an estimate that 4.4% of adults have an additional independent disorder named bipolar spectrum.

Other studies have produced substantially different figures by varying required symptoms, episode length, and methods of sampling. That disagreement is evidence of heterogeneity in case definitions and ascertainment, not a reason to select the largest figure as the definitive population burden. Epidemiologic subthreshold groups may also include individuals with highly varied severity, functional impact, and prognoses. Clinicians therefore evaluate a person's specific experiences and needs instead of inferring disease or treatment from a population percentage. Merikangas et al.; Nusslock and Frank.

Signs that can justify a closer bipolar assessment

A history merits closer evaluation when there are discrete periods of unusually elevated or irritable mood together with substantially increased energy or activity, sharply decreased need for sleep, more rapid or pressured speech, racing thoughts, increased goal-directed activity, uncharacteristic confidence or grandiosity, or unusually consequential risk-taking. Duration, recurrence, and noticeable departure from baseline matter. Changes may be reported by the person, family, colleagues, or clinical records. The NIMH symptom guide describes the clinically relevant symptom patterns.

In a broader spectrum assessment, a clinician will also ask whether depressive episodes have occurred, whether activation began after an antidepressant, stimulant, substance, corticosteroid, or another medication, and whether irregular sleep, major stress, thyroid disease, or other medical factors might explain the change. The timing relative to substances and medical conditions is especially important. A change that appears only during intoxication or a medication effect may require a different formulation from spontaneous recurrent mood episodes. The NICE assessment guidance explicitly requires a detailed lifetime and differential-diagnostic history.

How a clinician assesses possible spectrum features

Constructing a longitudinal episode timeline

The cornerstone is a chronological account of distinct mood episodes and intervening periods: approximate starting and ending dates, usual functioning before the change, sleep duration and perceived need for sleep, energy, speech, thought speed, judgment, work or school effects, interpersonal consequences, and any emergency care. Previous depressive episodes, psychotic symptoms, substance use, medications, family psychiatric history, and recurrence patterns belong on the same timeline. Clinical interpretation also needs contextual information: a week of little sleep while caring for a newborn does not have the same meaning as a week of feeling no need to sleep while exhibiting clear elevated-state symptoms. NICE.

Gathering corroboration while respecting autonomy

Friends or relatives may remember changes in speech, purchases, judgment, or sleep that the person did not experience as problematic. With the person's agreement, collateral descriptions can clarify the timing and observable extent of an episode. Hospital notes, prescription histories, and prior clinical assessments may offer additional information. The clinician should also ask about experiences of depression, trauma, anxiety, attentional difficulties, and psychosis without assuming they all represent bipolarity. NICE CG185 specifically recommends inviting a relative or caregiver to contribute when appropriate.

Separating a screening result from diagnosis

The Mood Disorder Questionnaire (MDQ) and Hypomania Checklist-32 (HCL-32) ask about lifetime activation symptoms and can prompt discussion in selected settings. Their sensitivity, specificity, and predictive value vary substantially by population, threshold, and the underlying prevalence of bipolar illness. A positive screen may reflect anxiety, ADHD, substance effects, personality-related dysregulation, or other experiences; a negative screen may miss bipolar presentations. A meta-analysis by Carvalho and colleagues examined the accuracy of bipolar-spectrum instruments. NICE explicitly advises against using questionnaires in primary care to identify bipolar disorder in adults. A screening score is never a stand-alone diagnosis. NICE CG185.

Assessing severity, impairment, and safety

The same symptom duration can have different clinical implications depending on the degree of change, functional consequences, and risk. A clinician should ask about missed work, impulsive spending, sexual or financial vulnerability, unsafe driving, interpersonal conflict, suicidal thoughts, self-neglect, and potential loss of capacity to make safe decisions. Assessment also includes medical conditions, comorbid disorders, personal recovery goals, and prior responses to treatment. These are core components of the NICE clinical assessment and risk guidance.

Conditions that can resemble bipolar spectrum presentations

Unipolar depression and mixed depressive symptoms

Major depressive disorder can occur with agitation, insomnia, anxiety, irritability, or changing energy. Such symptoms do not, by themselves, prove a history of hypomania. A clinician must establish whether an independent distinct activated episode occurred and whether the symptoms meet criteria for a bipolar or related diagnosis. Depressive episodes with some concurrent opposite-pole symptoms require careful characterization; the presence of a mixed-features specifier is not an automatic substitute for a bipolar diagnosis. NIMH; NICE CG185.

ADHD, borderline personality disorder, and anxiety

ADHD may involve long-standing distractibility, impulsivity, activity differences, and sleep difficulties, beginning in a developmental pattern rather than discrete changes in mood and energy. Borderline personality disorder can involve intense emotional reactions and interpersonal instability; these should be assessed on their own terms, including time course and triggers. Anxiety disorders may produce racing thoughts, insomnia, and agitation without an elevated mood episode. Comorbidity is also possible, so a clinician cannot decide by one shared symptom. The NICE guidance specifically lists these considerations and requires assessment for coexisting conditions.

Sleep loss, substances, medications, and physical illness

Sleep deprivation can intensify activation-like symptoms and can also precipitate episodes in vulnerable individuals. Stimulants, recreational substances, alcohol, prescribed medicines, and abrupt changes in treatment may complicate the history. Thyroid abnormalities and other medical illnesses can affect mood and energy. These factors call for medical and psychiatric assessment, medication review, and sometimes laboratory evaluation; no single laboratory test establishes a bipolar spectrum diagnosis. NICE CG185; VA/DoD guideline.

Can subthreshold symptoms develop into bipolar I or II?

Some people presenting with depression or initially subthreshold activation later experience an episode sufficient for a formal bipolar diagnosis. A prospective history is valuable because new information can change diagnostic formulation. In the long-term Collaborative Depression Study reported by Fiedorowicz and colleagues, baseline subthreshold hypomanic features were associated with later mania or hypomania. Importantly, association is a probability difference within the studied population, not a certainty for any individual. Most people reporting occasional activation do not thereby establish a future bipolar illness.

The possibility of later diagnostic change favors reassessment when new episodic symptoms appear, particularly when prior depressive episodes or a family history complicate the picture. It does not justify labeling everyone with brief energy fluctuations as pre-bipolar. Follow-up frequency and method should match the actual symptoms, degree of impairment, risk, and clinical judgment. Researchers still need prospective studies using consistent spectrum criteria, appropriate comparison groups, and meaningful functional outcomes to establish which subthreshold groups are most clinically informative. Nusslock and Frank; Fiedorowicz et al..

Does a bipolar spectrum description change treatment?

Treatment follows a clinical formulation, not an umbrella label

An umbrella spectrum formulation can guide investigation, risk assessment, monitoring, and referral. It is insufficient on its own to determine medication. The evidence that supports lithium or particular antipsychotics for established bipolar disorder cannot automatically be extended to anyone with a few hypomanic traits. Acute mania, bipolar depression, and relapse prevention are separate treatment questions, each with distinct evidence, licensing, adverse effects, and monitoring requirements. CANMAT/ISBD 2023 evidence update; VA/DoD 2023 guideline; NICE CG185.

Medication considerations and safety

If a formal bipolar disorder is established, care may include phase-appropriate medicines and psychotherapy. Lithium requires serum-level monitoring as well as assessment of renal and thyroid function, interactions, and toxicity risk. Lamotrigine requires gradual titration and urgent assessment of a concerning rash and is not recommended for treating acute mania. Valproate requires attention to liver and blood-related effects and important reproductive and pregnancy-related restrictions. Antipsychotics require monitoring for metabolic, movement-related, cardiovascular, and other adverse effects according to the agent. Such decisions belong in clinician-led, shared treatment planning and should not be made on the basis of the words bipolar spectrum alone. NICE CG185; CANMAT/ISBD update.

Antidepressant-associated activation requires special care in interpretation. Elevated or accelerated symptoms after a medication starts or changes may represent an adverse drug reaction, the expression of underlying bipolar susceptibility, or another clinical process; chronology and persistence matter. Gill and colleagues' review describes the disputed explanatory models, while the ISBD antidepressant task force report discusses treatment-associated switching concerns in diagnosed bipolar disorder. A possible spectrum description should prompt discussion with the prescriber, not independent initiation, stopping, or dose adjustment of medication.

Psychotherapy, sleep, and follow-up

Psychological care may address depressive symptoms, distress, emotional regulation, sleep routines, family communication, and functional recovery whether or not a bipolar disorder has yet been confirmed. For a diagnosed bipolar disorder, structured bipolar-specific interventions and relapse planning have recommendations in established guidelines. For an unconfirmed spectrum formulation, the clinician should select intervention targets based on demonstrable symptoms and needs rather than claim that bipolar-specific relapse-prevention trials prove efficacy for every subthreshold presentation. Collaborative symptom tracking and agreed follow-up can help detect meaningful changes over time. NICE CG185; VA/DoD guideline.

Risks of using the spectrum label too broadly

A broad label can validate real distress and identify people otherwise overlooked, but it can also convert transient human experiences into presumed pathology. False-positive identification can lead to unnecessary exposure to medications with significant adverse-effect profiles, reinforce an inaccurate personal narrative, or distract from a treatable alternative cause. Conversely, rigidly dismissing clear recurrent activated episodes because one historical period was shorter than a standard threshold may delay appropriate evaluation. The clinical answer is better description and longitudinal reassessment, with explicit uncertainty where warranted. The Carvalho meta-analysis demonstrates why screening performance varies, and NICE outlines the broader assessment required.

Diagnostic overreach can also occur in the opposite direction when a person's longstanding temperament, emotional reactivity, or exposure to stress is presumed to indicate occult bipolar illness. Biological research has not produced a diagnostic blood test, brain scan, genetic score, or temperament profile that independently confirms an informal bipolar spectrum disorder in a specific person. A family's history, medication sensitivity, and symptom questionnaires remain pieces of a clinical assessment rather than decisive proof. NIMH; NICE CG185.

Bipolar spectrum across different life stages

Children and adolescents

Mood variation, irritability, activity level, and sleep needs change during development. An assessment for a young person must account for developmental stage, corroborated distinct episodes, family and school functioning, neurodevelopmental conditions, trauma, substances, and physical health. Findings from adult spectrum prevalence or treatment studies do not automatically apply to adolescents. Specialist pediatric evaluation is important when sustained mania-like changes, severe depression, psychosis, or substantial impairment appear. NICE guidance for children and young people addresses these safeguards.

Pregnancy and the postpartum period

Pregnancy and the period following childbirth can complicate the interpretation of sleep loss, mood symptoms, medication changes, and the risk of severe affective episodes. A history suggestive of mania, hypomania, psychosis, or bipolar disorder warrants perinatal-specialist review. Medication risks and benefits differ greatly by drug and individual circumstances; in particular, valproate carries major reproductive hazards and restrictions. Anyone planning pregnancy or becoming pregnant while taking psychiatric medication should promptly discuss personalized care with their treating professionals rather than making abrupt medication changes. NICE CG185.

Older adults

New manic-like symptoms later in life require careful attention to medical conditions, neurocognitive illness, prescribed medications, and substances, alongside a longitudinal psychiatric history. A newly emerging mood disturbance should not be assigned an informal spectrum label before these alternatives are examined. Coexisting health conditions can also change the safety and monitoring of treatments. NICE recommends access to appropriate bipolar care for older adults while evaluating the individual's full clinical context. NICE CG185.

Practical questions to bring to an assessment

A useful appointment history describes concrete observations: What changed from my usual mood, energy, sleep, speech, or judgment? How many consecutive days did it last? Did I need less sleep, or was I tired but unable to sleep? Did anyone else notice? What were the consequences for work, study, finances, relationships, or safety? Were there separate episodes of depression? What medications, stimulants, substances, major stressors, medical problems, or disrupted schedules overlapped the change? Has anything similar happened before, and is there a family history of mood episodes? These questions reflect the longitudinal approach recommended in NICE CG185.

People already receiving care can ask what the clinician means by bipolar spectrum in their specific case: Is it a shorthand for a formally established disorder, an unresolved differential diagnosis, a documented subthreshold episode, or a research-style description? Which findings support that interpretation, which alternatives remain open, what are the treatment targets, and when should the formulation be reassessed? Clear answers improve shared decisions and keep exploratory language from silently becoming a permanent diagnosis.

When to seek urgent help

Seek urgent professional assessment when an individual develops markedly elevated or agitated mood with little need for sleep and escalating unsafe behavior, shows psychotic symptoms such as delusions or hallucinations, becomes unable to care for basic needs, or experiences severe depression with suicidal thoughts or intent. Emergency assistance is appropriate when there is immediate danger. In the United States, call 911 for immediate emergencies, or call or text 988 for suicide or mental health crisis support. Elsewhere, contact local emergency or crisis services. The urgency relates to the person's actual symptoms and safety, regardless of whether anyone has used the label bipolar spectrum. NICE CG185; NIMH.

Frequently asked questions

Is bipolar spectrum an official DSM-5-TR diagnosis?

No. It is a broad descriptive or research expression. A clinical evaluation may instead identify bipolar I disorder, bipolar II disorder, cyclothymic disorder, another specified or unspecified bipolar-related diagnosis, or a different condition. The diagnostic criteria of the relevant classification still apply. NIMH.

Can someone have bipolar-spectrum features without bipolar I or bipolar II?

Yes. Clinicians and researchers may describe observable activation or mood episodes that fall short of full criteria. Whether those experiences justify a formal other specified or unspecified bipolar-related diagnosis, monitoring, or a different explanation depends on impairment, symptom history, diagnostic rules, and differential assessment. The adjective spectrum alone decides none of these questions. NIMH; Nusslock and Frank.

Are brief hypomanic symptoms enough to diagnose bipolar II?

No. Bipolar II has specific requirements for a hypomanic episode, a major depressive episode, and the absence of a lifetime manic episode. Short or incomplete activation may be clinically relevant and deserving of monitoring, but a brief symptom cluster should not be relabeled as fully established bipolar II. NIMH.

Does a positive bipolar spectrum questionnaire mean I have bipolar disorder?

No. Screening instruments identify patterns for further assessment, and false-positive as well as false-negative results occur. The accuracy depends on the clinical population and instrument. A clinician assesses episodes, chronology, functional impact, alternative causes, and risk; NICE advises against questionnaire-based identification of adult bipolar disorder in primary care. Carvalho et al.; NICE CG185.

Will everyone with subthreshold features eventually develop bipolar disorder?

No. Longitudinal studies show increased risk in some defined groups, but prediction remains probabilistic and depends on how subthreshold symptoms were measured. Many people do not develop a subsequent syndromal elevated episode. Monitoring should respond to the person's clinical picture rather than an assumed inevitable progression. Fiedorowicz et al..

Can an antidepressant-induced high prove bipolar spectrum?

A treatment-emergent activated state is an important event to evaluate, especially if clear symptoms persist, but it cannot be interpreted in isolation as proof of a particular diagnosis. The timing, medication, dose change, full symptom pattern, persistence, and other medical or substance factors matter. Discuss such a reaction promptly with the prescriber rather than independently changing medication. Gill et al.; ISBD report.

Should a person described as bipolar spectrum take lithium?

That phrase alone provides no indication to begin lithium. Lithium can be an important treatment for formally diagnosed bipolar disorder, but prescribing requires a phase-specific clinical indication, individualized risk–benefit decisions, blood-level monitoring, kidney and thyroid assessment, and attention to interactions and toxicity. A clinician should explain the diagnosis or formulation supporting any proposed treatment. NICE CG185.

Can someone experience serious distress without meeting full bipolar criteria?

Yes. Symptom-related suffering, impaired sleep, depression, and compromised functioning merit evaluation and support even when a categorical diagnosis remains uncertain or another condition better explains the presentation. Clinical care can target those problems while the diagnosis is clarified. Spectrum terminology should not become a barrier to seeking help, and a person's experiences need not be exaggerated to deserve attention. NICE CG185.

Clinical conclusion

Bipolar spectrum is best understood as a variable clinical and research framework that draws attention to the range of bipolar-related features and subthreshold mood presentations. It offers useful questions about episode patterns, functional consequences, family history, risk, and prognosis. Its diagnostic limit is equally essential: the term does not supply a standardized independent diagnosis, prove a cause, predict inevitable conversion, or justify a particular medication. A defensible clinical formulation states what was observed, what criteria have and have not been established, which alternative explanations were considered, and how care and follow-up will respond to changing evidence. NICE CG185; CANMAT/ISBD.

Related Articles

References

Carvalho, A. F., Takwoingi, Y., Sales, P. M. G., et al. (2015). Screening for bipolar spectrum disorders: A comprehensive meta-analysis of accuracy studies. Journal of Affective Disorders, 172, 337–346. https://doi.org/10.1016/j.jad.2014.10.024.

Cassano, G. B., et al. (1999). The bipolar spectrum: A clinical reality in search of diagnostic criteria and an assessment methodology. Journal of Affective Disorders. PubMed record.

Fiedorowicz, J. G., Endicott, J., Leon, A. C., Solomon, D. A., Keller, M. B., & Coryell, W. H. (2011). Subthreshold hypomanic symptoms in progression from unipolar major depression to bipolar disorder. American Journal of Psychiatry, 168(1), 40–48. https://doi.org/10.1176/appi.ajp.2010.10030328.

Gill, N., Bayes, A., & Parker, G. (2020). A review of antidepressant-associated hypomania in those diagnosed with unipolar depression: Risk factors, conceptual models, and management. Current Psychiatry Reports. https://doi.org/10.1007/s11920-020-01143-6.

Keramatian, K., Chithra, N. K., & Yatham, L. N. (2023). The CANMAT and ISBD guidelines for the treatment of bipolar disorder: Summary and a 2023 update of evidence. Focus, 21(4), 344–353. https://doi.org/10.1176/appi.focus.20230009.

Merikangas, K. R., Akiskal, H. S., Angst, J., et al. (2007). Lifetime and 12-month prevalence of bipolar spectrum disorder in the National Comorbidity Survey Replication. Archives of General Psychiatry, 64(5), 543–552. https://doi.org/10.1001/archpsyc.64.5.543.

National Institute for Health and Care Excellence. (2025 update). Bipolar disorder: Assessment and management. Clinical guideline CG185. https://www.nice.org.uk/guidance/cg185/chapter/Recommendations.

National Institute of Mental Health. (n.d.). Bipolar disorder. https://www.nimh.nih.gov/health/publications/bipolar-disorder.

Nusslock, R., & Frank, E. (2011). Subthreshold bipolarity: Diagnostic issues and challenges. https://doi.org/10.1111/j.1399-5618.2011.00957.x.

Pacchiarotti, I., Bond, D. J., Baldessarini, R. J., et al. (2013). The International Society for Bipolar Disorders (ISBD) task force report on antidepressant use in bipolar disorders. American Journal of Psychiatry. https://doi.org/10.1176/appi.ajp.2013.13020185.

U.S. Department of Veterans Affairs & U.S. Department of Defense. (2023). VA/DoD clinical practice guideline for management of bipolar disorder. https://www.healthquality.va.gov/HEALTHQUALITY/guidelines/MH/bd/.

 
 
bottom of page